MX2015003535A - Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa. - Google Patents

Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa.

Info

Publication number
MX2015003535A
MX2015003535A MX2015003535A MX2015003535A MX2015003535A MX 2015003535 A MX2015003535 A MX 2015003535A MX 2015003535 A MX2015003535 A MX 2015003535A MX 2015003535 A MX2015003535 A MX 2015003535A MX 2015003535 A MX2015003535 A MX 2015003535A
Authority
MX
Mexico
Prior art keywords
compounds
dihydropyrrolidino
pyrimidines
kinase inhibitors
present
Prior art date
Application number
MX2015003535A
Other languages
English (en)
Inventor
Cynthia Shafer
Huw Tanner
Michael Patrick Dillon
Mika Lindvall
Daniel Poon
Savithri Ramurthy
Vivek Rauniyar
Sharadha Subramanian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015003535A publication Critical patent/MX2015003535A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona los compuestos de la fórmula (1), y las sales farmacéuticamente aceptables de los mismos: (ver Fórmula) como se describe adicionalmente en la presente. La presente invención proporciona además composiciones farmacéuticas que comprenden estos compuestos, y combinaciones que comprenden estos compuestos combinados o usados con un co-agente terapéutico, así como los usos terapéuticos de estos compuestos y composiciones. Éstos son útiles en el tratamiento de enfermedades, tales como cáncer, que están asociadas con la activación de ERK1 y/o ERK2, y en especial para los cánceres dependientes de la senda de MAPK que muestren resistencia a los productos terapéuticos para cáncer inhibidores de Raf y/o MEK.
MX2015003535A 2012-09-19 2013-09-17 Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa. MX2015003535A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702981P 2012-09-19 2012-09-19
PCT/US2013/060032 WO2014047020A1 (en) 2012-09-19 2013-09-17 Dihydropyrrolidino-pyrimidines as kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2015003535A true MX2015003535A (es) 2015-07-14

Family

ID=49274870

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003535A MX2015003535A (es) 2012-09-19 2013-09-17 Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa.

Country Status (13)

Country Link
US (1) US9546173B2 (es)
EP (1) EP2897961B1 (es)
JP (1) JP6186440B2 (es)
KR (1) KR20150056550A (es)
CN (1) CN104640865B (es)
AU (1) AU2013318283A1 (es)
BR (1) BR112015005982A2 (es)
CA (1) CA2882410A1 (es)
EA (1) EA201590600A1 (es)
ES (1) ES2612885T3 (es)
IN (1) IN2015DN01328A (es)
MX (1) MX2015003535A (es)
WO (1) WO2014047020A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013318283A1 (en) * 2012-09-19 2015-03-05 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors
CA3103711A1 (en) 2018-07-12 2020-01-16 UCB Biopharma SRL Spirocyclic indane analogues as il-17 modulators
WO2020243457A1 (en) * 2019-05-29 2020-12-03 Viogen Biosciences, Llc Compounds and therapeutic uses thereof
CN114502546A (zh) * 2019-08-01 2022-05-13 普拉特戈公司 晚期糖基化终产物的抑制剂
KR20220112777A (ko) * 2019-12-10 2022-08-11 에프. 호프만-라 로슈 아게 패러독스 파괴제로서의 새로운 braf 억제제
US11718610B2 (en) 2020-04-30 2023-08-08 Medshine Discovery Inc. Compounds containing benzosultam

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
DE60330485D1 (de) * 2002-07-15 2010-01-21 Merck & Co Inc Zur behandlung von diabetes
CA2547080A1 (en) * 2003-12-02 2005-07-28 Vertex Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors and uses thereof
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US8067591B2 (en) 2005-01-10 2011-11-29 Agouron Pharmaceuticals, Inc. Pyrrolopyrazole, potent kinase inhibitors
ATE527240T1 (de) 2005-12-13 2011-10-15 Schering Corp Polyzyklische indazol-derivate als erk-hemmer
NZ581698A (en) 2007-06-05 2012-09-28 Merck Sharp & Dohme Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) * 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012065935A1 (en) 2010-11-17 2012-05-24 F. Hoffmann-La Roche Ag Methods of treating tumors
MX339873B (es) * 2011-02-28 2016-06-15 Genentech Inc Inhibidores de serina/treonina cinasa.
AU2013225531A1 (en) 2012-03-02 2014-09-25 Forma Tm, Llc. Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives
AU2013318283A1 (en) * 2012-09-19 2015-03-05 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors

Also Published As

Publication number Publication date
EA201590600A1 (ru) 2015-07-30
CA2882410A1 (en) 2014-03-27
EP2897961B1 (en) 2016-10-26
ES2612885T3 (es) 2017-05-19
BR112015005982A2 (pt) 2017-07-04
CN104640865B (zh) 2018-05-11
IN2015DN01328A (es) 2015-07-03
KR20150056550A (ko) 2015-05-26
US20150274733A1 (en) 2015-10-01
EP2897961A1 (en) 2015-07-29
JP2015529248A (ja) 2015-10-05
JP6186440B2 (ja) 2017-08-23
CN104640865A (zh) 2015-05-20
WO2014047020A1 (en) 2014-03-27
US9546173B2 (en) 2017-01-17
AU2013318283A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
MX2016015743A (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa.
JO3452B1 (ar) بنزاميدات أمينو اريل مغاير كمثبطات كيناز
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
MY177344A (en) Compounds and their methods of use
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
IN2014KN02601A (es)
UA111386C2 (uk) Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
PH12016501160A1 (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
MX2015003535A (es) Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa.
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
PH12018502376A1 (en) Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
WO2014138616A3 (en) Pyrazole compounds and methods of use thereof
MY192305A (en) Bipyrazole derivatives as jak inhibitors
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази
MX2011003390A (es) Compuestos y composiciones útiles en el tratamiento de enfermedades cardiacas con efectos secundarios reducidos.